| Literature DB >> 32375045 |
Ofer Elhanani1, Tomer Meir Salame2, Jonathan Sobel1, Dena Leshkowitz3, Lital Povodovski1, Itay Vaknin1, Dror Kolodkin-Gal4, Michael D Walker5.
Abstract
The emerging appreciation of plasticity among pancreatic lineages has created interest in harnessing cellular reprogramming for β cell replacement therapy of diabetes. Current reprogramming methodologies are inefficient, largely because of a limited understanding of the underlying mechanisms. Using an in vitro reprogramming system, we reveal the transcriptional repressor RE-1 silencing transcription factor (REST) as a barrier for β cell gene expression in the reprogramming of pancreatic exocrine cells. We observe that REST-bound loci lie adjacent to the binding sites of multiple key β cell transcription factors, including PDX1. Accordingly, a loss of REST function combined with PDX1 expression results in the synergistic activation of endocrine genes. This is accompanied by increased histone acetylation and PDX1 binding at endocrine gene loci. Collectively, our data identify a mechanism for REST activity involving the prevention of PDX1-mediated activation of endocrine genes and uncover REST downregulation and the resulting chromatin alterations as key events in β cell reprogramming.Entities:
Keywords: PDX1; REST; beta cells; chromatin; diabetes; enhancer; insulin; pancreas; reprogramming; trans-differentiation
Mesh:
Substances:
Year: 2020 PMID: 32375045 DOI: 10.1016/j.celrep.2020.107591
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423